RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The …
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for blood cancer patients: canakinumab trial targets Low-Risk MDS and CMML
Disease control Recruiting nowThis study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The drug is a lab-made antibody that may help slow cancer growth and improve blood cell counts. About 76 adults will rece…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug combo offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a chemotherapy drug called CPX-351 in people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) that came back or didn't respond to standard treatment. The goal is to find the best dose that is safe and to se…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Supercharged immune cells take on relapsed leukemia
Disease control Recruiting nowThis early-phase trial tests a new immunotherapy for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered donor T cells designed to recognize and attack a protein called HA-1 found …
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo attack on tough blood cancers: chemo plus transplant shows promise
Disease control Recruiting nowThis study tests a new approach for adults with aggressive blood cancers (like AML) that are likely to return after standard treatment. Participants receive a combination of chemotherapy drugs (decitabine plus FLAG-Ida) and low-dose radiation, followed immediately by a stem cell …
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study is for people with certain blood cancers (like acute myeloid leukemia) that have a specific genetic change called a FLT3 mutation. The cancers have either come back or not responded to prior treatment. The trial tests a combination of three drugs—azacitidine, venetocla…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New combo attack on stubborn leukemia: chemo then transplant
Disease control Recruiting nowThis early-phase trial tests a two-step approach for people with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. First, patients receive intensive chemotherapy (CLAG-M or FLAG-Ida) followed immediately by a reduced-intensity stem …
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New pill Q702 aims to outsmart blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…
Matched conditions: RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC